Abstract:Chronic hepatitis B virus (HBV) infection remains a leading cause of hepatic inflammation and damage. The pathogenesis of chronic hepatitis B (CHB) infection is predominantly mediated by persistent intrahepatic immunopathology. With the characterization of unique anatomical and immunological structure, the liver is also deemed an immunological organ, which gives rise to massive cytokines and chemokines under pathogenesis conditions, having significant implications for the progression of HBV infection. The intrahepatic innate immune system is responsible for the formidable source of cytokines and chemokines, with the latter also derived from hepatic parenchymal cells. In addition, systemic cytokines and chemokines are disturbed along with the disease course. Since HBV is a stealth virus, persistent exposure to HBV-related antigens confers to immune exhaustion, whereby regulatory cells are recruited by intrahepatic chemokines and cytokines, including interleukin-10 and transforming growth factor β, are involved in such series of causal events. Although the considerable value of two types of available approved treatment, interferons and nucleos(t)ide analogues, effectively suppress HBV replication, neither of them is sufficient for optimal restoration of the immunological attrition state to win the battle of the functional or virological cure of CHB infection. Notably, cytokines and chemokines play a crucial role in regulating the immune response. They exert effects by directly acting on HBV or indirectly manipulating target immune cells. As such, specific cytokines and chemokines, with a potential possibility to serve as novel immunological interventions, combined with those that target the virus itself, seem to be promising prospects in curative CHB infection. Here, we systematically review the recent literature that elucidates cytokine and chemokine-mediated pathogenesis and immune exhaustion of HBV infection and their dynamics triggered by current mainstream anti-HBV therapy. The predictive value of disease progression or control and the immunotherapies target of specific major cytokines and chemokines in CHB infection will also be delineated.

Interleukin-21 inhibits HBV replication in vitro.

Role of Interleukin-21 in HBV Infection: Friend or Foe?

Interleukin 21 Reinvigorates The Antiviral Activity Of Hepatitis B Virus (Hbv)-Specific Cd8(+) T Cells In Chronic Hbv Infection

JAK/STAT Signaling is Involved in IL-35-induced Inhibition of Hepatitis B Virus Antigen-Specific Cytotoxic T Cell Exhaustion in Chronic Hepatitis B

High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B.

Cytokines and Chemokines in HBV Infection

Interleukin-21 modulates balance between regulatory T cells and T-helper 17 cells in chronic hepatitis B virus infection

Seroconversion Through IL-21 in Patients with Chronic HBV Infection

IL-35 Inhibits HBV Antigen-Specific IFN-γ-producing CTLs in Vitro.

Interleukin-34 inhibits hepatitis B virus replication in vitro and in vivo

Interleukin 21 Augments the Hepatitis B Virus-Specific CD8+ T-cell Response in Vitro in Patients Coinfected with HIV-1.

Interleukin-33 Mediates Both Immune-Related and Non-Immune-related Inhibitory Effects Against Hepatitis B Virus

Interleukin-8 in HepG2 cells: Enhancing antiviral proteins in uninfected cells but promoting HBV replication in infected cells

Interleukin‐15 Suppresses Hepatitis B Virus Replication Via IFN‐β Production in a C57BL/6 Mouse Model

The analysis of IL-21 and its significance in acute hepatitis B patients

Serum IL-21 Levels Associated with Chronic Hepatitis B and Hepatitis B-related Liver Failure.

Characterization of IL-21-expressing recombinant hepatitis B virus (HBV) as a therapeutic agent targeting persisting HBV infection

Prior transient exposure to interleukin-21 delivered by recombinant adeno-associated virus vector protects mice from hepatitis B virus persistence.

IL-35: A Novel Immunomodulator in Hepatitis B Virus-Related Liver Diseases.

IL-21-based therapies induce clearance of hepatitis B virus persistence in mouse models.

IL21 and IL21R Polymorphisms and Their Interactive Effects on Serum IL-21 and IgE Levels in Patients with Chronic Hepatitis B Virus Infection.